Navigation Links
Two New Drug Combos May Fight Advanced Breast Cancers
Date:12/8/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Dec. 7 (HealthDay News) -- Breast cancer researchers report they are heartened by the results of two new studies that show combination therapies might improve survival for women with two different types of advanced tumors.

One of the drugs, everolimus (Afinitor), boosted progression-free survival in women with hormone receptor-positive breast cancer but is not yet approved by the U.S. Food and Drug Administration for this indication. The other drug, pertuzumab, improved survival with HER-2 positive tumors, but has not received any FDA approval.

So, the immediate clinical implications are probably "none," said Dr. Jose Baselga, lead author of both studies, which are to be presented at the 2011 San Antonio Breast Cancer Symposium Wednesday and published simultaneously in the New England Journal of Medicine.

In time, though, they could be "practice-changing," said Baselga, chief of hematology/oncology at Massachusetts General Hospital Cancer Center in Boston. "The benefits were very significant."

In the first study, 724 postmenopausal women with hormone receptor-positive breast cancer were randomly assigned to receive the aromatase inhibitor Aromasin (exemestane) plus a placebo or Aromasin plus Afinitor, which is already approved for treatment of kidney cancer.

Women receiving Afinitor lived an average of 7.4 months without a recurrence, versus only 3.2 months in the placebo group.

Half of the women receiving Afinitor showed some kind of tumor response compared to 25 percent in the control group.

"This is one of the most positive studies in hormone receptor-positive breast cancer," said Baselga.

It's not clear yet whether the drug improves overall survival, said the authors of the study, which was funded by Afinitor's maker, Novartis.

The second study involved 808 patients with HER2-positive breast cancer which had already spread to other parts of the body.

HER2-positive breast cancer, which accounts for roughly 20 percent of all breast cancers, is commonly treated with Herceptin (trastuzumab) and chemotherapy. Here, participants were randomly given Herceptin, chemotherapy and a placebo or Herceptin, chemotherapy and pertuzumab.

Women receiving pertuzumab went an average of 18.5 months before experiencing a recurrence compared to 12.4 months in the control group, a 38 percent reduction in risk.

"A six-month improvement is very good," Baselga said.

Herceptin and pertuzumab both block the HER2 growth factor, which causes these types of tumors to proliferate, although the drugs bind to different parts of the HER2 protein. But, pertuzumab goes a step further and suppresses HER2 from binding to HER3 growth factor receptors.

This study was funded by F. Hoffman-La Roche and Genentech, which make pertuzumab.

Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La., said the results were "intriguing" and "could potentially be very helpful in patients with two specific subsets of breast cancer."

But he also pointed out that both drugs are very expensive (possibly up to several thousand dollars a month) and are not yet approved for these specific uses.

"As these studies mature, this will be looked at by physicians around country to try to help patients," he said.

More information

The U.S. National Cancer Institute has more on targeted therapies for breast cancer.

SOURCES: Jose Baselga, M.D., Ph.D., chief, hematology/oncology, Massachusetts General Hospital Cancer Center, Boston; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La; Dec. 7, 2011, presentation, San Antonio Breast Cancer Symposium; Dec. 8, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Jeopardy! winnings spur IBM and Scripps Research Institute collaboration to fight against malaria
2. Losing Weight May Help Fight Gum Disease
3. Discovery may help fight late-stage ovarian cancer
4. Report identifies community health centers as Americas first responders in fighting obesity
5. Current training programs may not prepare firefighters to combat stress
6. Fighting fire with fire: Vampire bacteria has potential as living antibiotic
7. Fighting breast cancer early, one cell at a time
8. Fighting a smarter war against cancer
9. Hockey Fistfights Rarely Cause Injuries, Study Claims
10. More evidence that allergies may help in fighting brain tumors
11. Drug Combo Might Fight Aggressive Breast Cancer More Safely
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Two New Drug Combos May Fight Advanced Breast Cancers
(Date:1/16/2017)... ... ... Louisans are well-aware of the following facts at present:, Flu ... having no effect on keeping this particularly bad strain of the flu away , ... or sniffling , These facts are well-known among the team at Woodard! ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... San Francisco ... iTero Element, the latest in 3-D scanning device which is capable of taking digital ... latest advances in dentistry, such as CAD CAM restorations , in terms of ...
(Date:1/15/2017)... Cary, NC (PRWEB) , ... January 15, 2017 , ... Whole Health Supply, LLC is ... CP-140L . There are also new avenues for purchase. , The 2017 edition has ... can cause issues for the older boomers as well as diabetics. This handle is reinforced ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor ... Radnor, Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, the ... sixth location, including three in New Jersey and two in New York. With this ...
(Date:1/14/2017)... ... January 14, 2017 , ... "TransFreeze Volume 3 is a self animating masking transition ... in Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... freeze frame transition from one clip to the next. , To use “Cut-Out ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... Jan. 14, 2017  Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... According ...
(Date:1/13/2017)... -- Eli Lilly and Company (NYSE: LLY ... announced today that the U.S. Food and Drug Administration ... drug application (NDA) for investigational baricitinib, a once-daily oral ... arthritis (RA). The NDA for baricitinib was submitted to ... extended the action date to allow time to review ...
(Date:1/13/2017)... York , January 13, 2017 ... prevalence of AIDS will collectively contribute to the demand for ... to reach a value of US$ 551.0 Mn by 2016 ... will remain the most lucrative markets for western blotting, whereas ... the market globally. ...
Breaking Medicine Technology: